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Abstract
Biomathematical modeling quantitatively describes the disposition of metal nanoparticles in lungs 
and other organs of rats. In a preliminary model, adjustable parameters were calibrated to each of 
three data sets using a deterministic approach, with optimal values varying among the different 
data sets. In the current effort, Bayesian population analysis using Markov chain Monte Carlo 
(MCMC) simulation was used to recalibrate the model while improving assessments of parameter 
variability and uncertainty. The previously-developed model structure and some physiological 
parameter values were modified to improve physiological realism. The data from one of the three 
previously-identified studies and from two other studies were used for model calibration. The data 
from the one study that adequately characterized mass balance were used to generate parameter 
distributions. When data from a second study of the same nanomaterial (iridium) were added, the 
level of agreement was still acceptable. Addition of another data set (for silver nanoparticles) led 
to substantially lower precision in parameter estimates and large discrepancies between the model 
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predictions and experimental data for silver nanoparticles. Additional toxicokinetic data are 
needed to further evaluate the model structure and performance and to reduce uncertainty in the 
kinetic processes governing in vivo disposition of metal nanoparticles.
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1. Introduction
The use of nanoparticles in commerce has expanded rapidly, with an increase from 803 
products in 2008 to 1628 products as of October 2013 in a nanotechnology consumer 
products database (Project on Emerging Nanotechnologies, 2013). As consumer exposure 
increases, concerns about toxicity have also been raised, based on effects identified in 
laboratory animals. As in other areas of chemical toxicology, the development of 
physiologically based pharmacokinetic (PBPK) dosimetry models has the potential to 
improve understanding of concerns identified in rodents and the potential relevance to 
humans, based on comparative internal dosimetry. The fate of nanoparticles is an active area 
of research.
A biomathematical model was previously developed for the disposition of nanoparticles in 
rats (MacCalman et al., 2009; MacCalman and Tran, 2009) based on calibration to three data 
sets (Semmler et al., 2004; Takenaka et al., 2001; Fabian et al., 2008). In the preliminary 
model, adjustable parameters were calibrated for each data set using least squares methods, 
with varying values for a given parameter obtained for the different data sets. Some of these 
parameter values differed radically among data sets. For example, the estimates of fractional 
translocation from the liver capillaries to the venous blood ( ) were 0.9786 (Semmler), 0.5 
(Takenaka) and 0.0001 (Fabian). As these data sets describe the disposition of three different 
types of nanoparticles, it is unclear whether the parameter differences were due to material-
specific differences in disposition, inadequate data to unambiguously identify model 
parameter values, or an inappropriate model structure.
In the current model, Bayesian population analysis using Markov chain Monte Carlo 
(MCMC) simulation was performed to provide estimates of the parameter distributions 
(rather than point estimates), which also allowed for subsequent uncertainty and variability 
analysis. Bayesian population analysis is an appropriate method for calibrating the rat 
nanoparticle PBPK model (Bernillon and Bois, 2000; Lunn et al., 2009; Jonsson and 
Johanson, 2003; Hack, 2006; Hack et al., 2006; Péry et al., 2009). Using this technique, the 
model parameters were calibrated to one or more data sets simultaneously. Data from one of 
the three previously-identified studies were used; additional data useful for model 
calibration were extracted from one of these previously identified studies (described in more 
detail in the “Methods” section) and from a newly published study of nanoparticle 
toxicokinetics. The previously-developed model structure was modified and some 
physiological parameter values modified to improve physiological realism or simplify the 
model structure, based on published PBPK modeling of nanoparticles in rats and humans.
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A sensitivity analysis of the adjustable model parameters was conducted to assess the impact 
of uncertainty/variability in model parameter values to predictions of output, using the 
population posterior distribution as inputs for Monte Carlo simulations.
2. Materials and methods
2.1. Key data sets
The preliminary rat PBPK model for nanoparticles (MacCalman et al., 2009; MacCalman 
and Tran, 2009) was based on calibration to three data sets (Semmler et al., 2004; Takenaka 
et al., 2001; Fabian et al., 2008). (Key characteristics of these studies and others used in the 
model calibration are summarized in Table 1). For the preliminary model, the iridium data 
initially reported in Semmler et al. (2004) (with additional detail reported by Semmler-
Behnke et al., 2007) constituted the key data set for understanding rat whole-body 
disposition of nanoparticles due to the extended follow up time (longer than Takenaka et al., 
2001) and the measurement of nanoparticles in most of the tissue regions of interest 
(particles were not observed in the brain, olfactory, alveolar, and upper airway regions in the 
i.v. study by Fabian et al., 2008; which was also reported in van Ravenzwaay et al., 2009).
Based on literature searches, additional data sets that could potentially be used to further the 
development of this model were identified. The studies under consideration were limited to 
a narrow range of particles sizes (15–30 nm) (Table 1) due to findings that particles of 
approximately 20 nm diameter behave differently in vivo than larger (80–100 nm) particles 
(Sarlo et al., 2009; Lankveld et al., 2010). Furthermore, nanoparticles between 6 nm and 34 
nm are expected to result in the greatest internal tissue exposure, relative to other particle 
sizes (Choi et al., 2010). Additional desirable characteristics for candidate studies were the 
availability of time course data (vs. disposition at a single sampling time) and potential for 
mass balance (extensive tissue sampling and/or excretion data). Studies with a duration of 7 
days or more, and the use of non-functionalized metal particles were preferred due to greater 
comparability to the key data (Semmler et al., 2004). Potentially applicable new data sets 
included studies by Zhu et al. (2009) (ferric oxide), Lankveld et al. (2010) (silver), 
Dziendzikowska et al. (2012) (silver), and Shinohara et al. (2014) (titanium dioxide); the 
data of Sarlo et al. (2009) could not be used because nanoparticle recovery for most tissues 
was reported in semi-quantitative form (i.e., 0.005–0.05% of dose). In addition, another 
study of iridium nanoparticles from the same laboratory as the Semmler et al. (2004) study 
(Kreyling et al., 2002, 2009) was identified and the additional data deemed useful for the 
development of this model. The data of Zhu et al. (2009) were not used due to uncertainty 
regarding the distribution of intratracheally instilled particles within the airway. A portion of 
the study of Lankveld et al. (2010) was conducted using particles similar in size to the 
previously identified data, the study duration was similar, and the data were provided in a 
convenient tabular form, so these data were also used in model development (Table 1). The 
Dziendzikowska et al. (2012) concentration data were reported in terms of dry weight of 
tissue or feces; conversion factors were not provided, so this data set could not readily be 
used for model development. In the Shinohara et al. (2014) study, titanium dioxide was 
measured as titanium metal (Ti); since Ti in excreta were not elevated above the substantial 
levels in controls, mass balance could not be adequately characterized.
Sweeney et al. Page 3
Regul Toxicol Pharmacol. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The data of Semmler et al. (2004), reported in graphical form, were digitized. Whole body 
retention and fractional excretion rate data were used to compute cumulative fecal excretion 
of nano-particles (not used in the preliminary model) and fractional retention in the lung 
(normalized to retention on day 3) was converted to absolute amounts.
The data for the study of Takenaka et al. (2001) were reported in tabular form. We were not 
able to successfully simulate this scenario, due to simulation errors (negative amounts of 
mass predicted, most frequently in smaller tissues) encountered when attempting to simulate 
this study using the MCSim software. Furthermore, this study used a different animal model 
than other studies under consideration (female F344 rats vs. male Wistar rats), so solutions 
to the simulation difficulties were not pursued and this data set was not used in the current 
evaluation.
The data of Lankveld et al. (2010) were reported both in graphical form as concentrations, 
and in tabular form as whole-organ values. The whole organ values were used, with the 
exception that the blood values were multiplied by 1/3 to estimate the amount of particles 
present in the venous blood only, based on rat anatomy and the model structure, which 
separates venous, arterial, and capillary blood.
The data of Fabian et al. (2008) were reported as tissue concentrations of nanoparticles. 
These concentrations were scaled to whole-organ values using average organ masses 
provided in the same paper. On Day 1, the sum of these scaled amounts (1.37 mg) slightly 
exceeded the administered dose (1.25 mg). To avoid mass balance issues associated with 
this discrepancy, the amounts of nanoparticles in all tissues on day 1 were adjusted such that 
the total body burden equaled the administered dose.
2.2. Model structure
The model structure (Fig. 1) was a revision of the structure proposed by MacCalman and co-
workers (MacCalman et al., 2009; MacCalman and Tran, 2009); the MacCalman et al. 
PBPK model was an extension of earlier models describing the retention and clearance of 
particles in the lung (Tran et al., 2002; Tran et al., 2001). The multi-compartmental structure 
(i.e., “splitting” rather. than “lumping”) was dictated by consideration of the data available 
and physiological processes of interest. For example, the availability of particle 
concentration data for a number of distinct tissues that are sometimes lumped in PBPK 
models (e.g., brain, heart, spleen) meant that these tissues could be considered separately. 
Physiological processes of interest included a realistic representation of arterial plus portal 
flow to the liver and potential enterohepatic recirculation. Revisions were made to improve 
the physiological realism of the extrarespiratory portions of the model. Briefly, the model 
describes each non-respiratory organ as consisting of tissue and tissue capillaries (liver 
tissue shown in Fig. 2; other tissues have the same subcompartments, but no biliary 
excretion). Arterial blood carrying nanoparticles enters the tissue capillaries, and 
nanoparticles diffuse into the tissue. Nanoparticles within the tissue can either be quasi-
irreversibly sequestered or diffuse back into the tissue capillaries, from which they may exit 
in the venous blood. As implemented for this effort, parameter values for diffusion are set 
such that there is no diffusion limitation. In the revised model structure, the venous blood of 
the splanchnic tissues (spleen and gastrointestinal tract [GI]) is delivered to the liver 
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capillaries rather than the venous blood, as in the MacCalman et al. model in order to be 
more physiologically realistic. The GI tract includes a “gut contents” subcompartment in 
addition to the tissue and capillaries. Nanoparticles may reach the gut contents via gavage; 
direct oral ingestion; clearance from the olfactory region, upper airways, or alveolar region; 
or biliary elimination from the liver. The nano-particles in the gut contents may be absorbed 
into the GI capillaries (and distributed systemically from there) or excreted from the body in 
the feces. The biliary elimination of nanoparticles from the liver is assumed to occur via 
partitioning from liver tissue to bile and transport of the bile into the gut contents.
The “bound” material in the organs is eliminated from the “sequestered” subcompartment 
into the feces. This mathematical description is a simplistic description of undetermined 
processes. The nature of the bound material is unknown, but may be sequestered, 
phagocytized material in immune cells (Li et al., 2014) or strongly bound to protein. 
Attempts to describe the entire nanoparticle content of systemic tissues as freely 
exchangeable with blood or limited by diffusion only were unsuccessful. However, to 
simulate the long-term time course of nanoparticles in systemic tissues, some form of 
clearance must be included, although this pathway appears to provide a relatively small 
contribution to total clearance. It was assumed that, once sequestered, the nanoparticles 
would not again become “free” particles available for uptake from blood or GI contents. 
Therefore their tissue clearance was described as direct elimination via feces. Simplified 
descriptions of elimination pathways for excretion via urinary, fecal, and/or exhaled breath 
pathways (e.g., Hays et al., 2000; Louisse et al., 2010; Kim et al., 1994; Thrall et al., 2000) 
are common in PBPK modeling, due to limited data availability for parameterizing clearance 
(Clark et al., 2004).
2.3. Model parameter values
Anatomical and physiological parameters for a “standard” 250 g rat were generally taken 
from the preliminary model (MacCalman et al., 2009; MacCalman and Tran, 2009) and are 
reported in Table 2. The computation of the “other tissues” volume was corrected so that it 
was calculated by mass balance. Bile flow from the liver to the gut contents was added at a 
rate of 20 ml/day (RIVM, 2010) so that transfer of nanoparticles from the liver to the gut 
contents could be calculated based on bile:liver tissue partitioning and bile flow.
The parameters controlling the diffusion of nanoparticles between capillary blood and 
tissues were set equal to 1 so that the diffusion limitation would effectively be removed. 
This change was based on the findings of Péry et al. (2009) that diffusion limitations were 
not necessary to adequately describe the kinetics of 99mtechnetium-labeled carbon 
nanoparticles in humans and because in the MacCalman and Tran (2009) optimization to the 
Semmler et al. (2004) data, most of the values for fractional translocation from capillaries to 
tissues were similar to 1 (spleen and kidney were exceptions to this finding).
Particle size-specific estimates of airway deposition in the various regions for which 
calibration data are available were calculated for both normal and endotracheal inhalation 
using the MPPD2 model (v. 2.11, Applied Research Associates, Albuquerque, NM). 
Fractional deposition estimates for endotracheal inhalation of iridium were determined using 
MPPD2 based on the particle and exposure characteristics described in Semmler et al. 
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(2004)/Semmler-Behnke et al. (2007) and Kreyling et al. (2002, 2009). Calculated 
deposition fractions were 0.2371 for the upper airways (conducting airways, in MPPD) and 
0.4203 for the alveolar region for the Semmler study and 0.2657 for the upper airways and 
0.4461 for the alveolar region for the Kreyling study. Similar calculations were done to 
estimate deposition for the Takenaka et al. (2001) data, but are not described here because 
these data were not used.
In the preliminary model, the fractions of the nanoparticles cleared from the airways into the 
gut contents were allowed to be adjustable (optimized) parameters. In the current model, 
100% transfer of cleared nanoparticles into the gut contents was assumed, an approximation 
that is likely to be accurate for airway clearance in rats (because it is unlikely that coughing 
or sneezing would be significant in rats).
In the preliminary model, the rate constants for processes in the alveolar region (particle 
uptake, release, and clearance by macrophages and the particle interstitialization rate) were 
taken from an earlier model for silica (Tran et al., 2002; Tran et al., 2001). For the current 
effort, this assumption was initially relaxed, and attempts were made to estimate these 
parameter values for nanoparticles. However, it was found that these parameters could not 
be unambiguously identified from the existing data (i.e., the parameter values did not 
converge when multiple chains of simulations were completed), so the values used in the 
preliminary model were used for further analyses.
Urinary elimination of nanoparticles was included in the preliminary model. Lankveld et al. 
(2010) found that multiple routes of nanoparticle clearance (i.e., urinary and fecal) could not 
be clearly distinguished in their model (based only on tissue concentrations from their own 
data set; they did not measure nanoparticle mass in excreta) and Choi et al. (2007) 
determined that urinary elimination is unlikely for nanoparticles larger than 5.5 nm. 
Therefore, the urinary clearance in the model was effectively “turned off” by setting the 
kidney clearance rate (κ54) to zero. In the human nanoparticle PBPK model developed by 
Péry et al. (2009), the same value was used for all tissue:plasma partition coefficients. Based 
on their results, the possibility of making all tissue:plasma partition coefficients equal was 
tested, but did not improve model fits for these data (not shown), so tissue-specific 
tissue:plasma partition coefficients were retained in the model.
In the preliminary model, sequestration of nanoparticles in tissue was assumed to be 
irreversible. Because shorter term models (e.g., Péry et al., 2009) were able to simulate 
nanoparticle tissue kinetics with partition coefficients only (no binding), it was hypothesized 
that the longer-term declines in tissue nanoparticle levels were due to slow clearance of 
sequestered material by un-identified processes (possibly via trafficking of phagocytes, or 
protein turnover). This clearance process was assumed to be governed by first-order 
kinetics.
The fecal elimination rate was a fully adjustable parameter in earlier versions of the revised 
model. Because unrealistically high rates for this parameter were estimated in the 
optimization, the population mean was fixed at 8.2/day, based on the half time for the 
passage of material from the stomach to the cecum (Enck et al., 1989). The absorption rate 
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from the GI tract to the portal vein blood was allowed to vary for individual studies, within 
the constraints of the population parameters.
2.4. Model implementation/model calibration
The preliminary rat PBPK model was previously developed by one of the coauthors (Laura 
MacCalman) in Matlab. The equations were modified per the model structural changes 
noted above and converted into a format appropriate for MCSim (version 5.3.1). The model 
text file was converted into a C file using the preprocessor “mod” and was subsequently 
compiled into the executable program.
The Bayesian approach relies on both prior knowledge, as described in initial parameter 
distributions (shapes and ranges of values), and information that (if analyzed appropriately) 
can be deduced from the measured data (Gelman et al., 1996; Bernillon and Bois, 2000). 
Using a sampling algorithm such as the Metropolis Hastings algorithm, proposed 
distributions are tested and narrowed to identify distributions that produce the best 
agreement between the model and the data. In these stochastic simulations, the selection of 
subsequent random values is influenced by the current parameter values (Bois and Maszle, 
2009), with the goal that, on the whole, agreement improves as the simulation progresses. 
Each chain should be inspected to verify that “equilibrium” has been achieved, and multiple 
chains with different starting values (seed values) should be executed to test for consistency 
among chains.
To facilitate the Bayesian MCMC analysis, a statistical model was generated to implement a 
Bayesian approach to modeling the data. For the statistical model, the parameters to be 
sampled and optimized were transformed so that the parameters would be described by 
distributions of the means of the natural logarithm of the parameter value (M_lnParam) and 
the associated variances (V_lnParam). The variance of the measurement error for the 
measured covariates was also specified (Ve_Meas). The distribution shapes were modeled 
after those used in development of the trichloroethylene PBPK model (U.S. EPA, 2009; 
Evans et al., 2009; Chiu et al., 2009), and reflect to the degree possible the known, empirical 
distributions of values in variable human populations. The distributions for M_lnParam were 
generally truncated normal distributions, while the V_lnParam values were assumed to 
follow an inverse gamma distribution (see “Results”, Table 3, and Supplementary Materials, 
Tables S-1 and S-2). The Ve_Meas distributions were characterized as log uniform. Highly 
uninformative prior parameter distributions were used to avoid bias, so that the posteriors 
were determined by the data alone.
Multiple chains of MCMC simulations (10,000 iterations per chain, results reported for 
every fifth iteration) were produced by using different seed values for the MCMC algorithm. 
Occasionally chains produced fatal errors; when this happened, such events typically 
occurred early in the chain and the results were discarded. This problem was encountered 
more frequently when multiple data sets were considered simultaneously. Preliminary 
analyses of the chains consisted of evaluating the progress of the chain by viewing the 
changes in the log likelihood function (LLF) as the iterations progressed (a larger LLF 
indicates better agreement between the model predictions and experimental data). This 
inspection ensured that the chain was sufficiently stable that the last 5000 iterations would 
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yield an acceptable set of “optimal” parameter values from the chain. An example of the 
stabilization of the LLF output is provided in the Supplementary Materials (Fig. S-1). When 
three acceptable chains had been produced, an initial assessment of the consistency of the 
results was made by comparing the average of the LLFs. Typically, if there appeared to be 
disparate results, additional chains were produced (up to a total of six chains) and the three 
with the highest LLFs were used in subsequent analyses (e.g., convergence, posterior 
parameter estimates).
2.5. Evaluation of model output
2.5.1. Convergence of model parameter estimates—The convergence (similarity) 
of results among chains was analyzed by comparing the means and variances of the 
parameter estimates through the use of the “R” statistic, where R = 1 indicates perfect 
convergence (Gelman and Rubin, 1992; Gelman, 1996; Gelman et al., 1996). Gelman et al. 
(1996) indicated that PBPK model parameter value estimates demonstrated acceptable 
convergence if √R < 1.2 (R < 1.44). In the MCMC output summaries (Table 3, Tables S-1, 
and S-2), the posterior variances (in the column to the left of the “R” value) reflect the 
average variance in posterior values the three chains used for a particular data set (or group 
of data sets). That is, for a series in which the first three chains were deemed to adequately 
converge, the reported posterior variance is 1/3rd of the sum of variance of posterior values 
from chain 1, chain 2, and chain 3. These variances among output values of each chain 
should not be confused with the population parameter variances, the posterior mean value 
for V_lnParam.
2.5.2. Model sensitivity analyses—Key (sensitive) adjustable model parameters were 
identified by using the posterior parameter values derived from the MCMC analysis of the 
Semmler et al. (2004)/Semmler-Behnke et al. (2007) and Kreyling et al. (2002, 2009) data. 
The model was implemented in acslX (version 3.0.2.1, AEgis Technologies, Huntsville, AL, 
USA) using the Monte Carlo analysis utility to generate 1000 model iterations. The 
population means and variances noted in bold in Table 3, Tables S-1, and S-2 and the prior 
constraints (minimum and maximum values) were used to generate the parameter values for 
the Monte Carlo simulations. Sensitivity was determined at a limited number of times that 
corresponded to the times at which experimental data had been collected. Because non-
normal distributions were used, inputs and outputs were converted to ranks (i.e., the lowest 
value is assigned a rank of 1000, whereas the highest value is assigned a rank of 1) prior to 
correlation analysis (Decisioneering, 1996). The correlation between ranks was determined 
using Microsoft Excel (“CORREL” function). The contribution of a given parameter to the 
variance of the forecast value is determined by squaring the correlation coefficients of the 
input parameters and normalizing each input to a total contribution of 100 percent 
(Decisioneering, 1996).
2.5.3. Visualization of output—The forecast values from the Monte Carlo simulations 
were compared to the experimental data using plots generated in Microsoft Excel. Time 
course simulations of measurements of interest were extracted for the median output of the 
population simulation and the 16th and 84th percentile values. For normally distributed 
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outputs, the 16th and 84th percentile values approximate values ± one standard deviation 
from the mean.
2.5.4. Quantification of extent of agreement between model predictions and 
experimental data—For each experimental data point, the agreement between the model 
prediction and the experimental value (discrepancy index) was computed as the maximum 
of the predicted value/experimental value or experimental value/predicted value. In the case 
of perfect agreement between the model and the data, the discrepancy index would be 1. 
Geometric mean discrepancy indices were computed to aggregate the discrepancy indices 
for tissues/excreta over time and for all times and matrices evaluated for a given study. The 
agreement between the model and data was generally deemed acceptable if, on average, the 
difference between the model predictions and the mean of the experimental data is not more 
than a factor of two (International Programme on Chemical Safety [IPCS], 2010).
3. Results
The current model calibration was based mainly on data from three studies, including the 
Semmler study (Semmler et al., 2004; Semmler-Behnke et al., 2007) that was used in the 
earlier model (MacCalman and Tran, 2009). The Semmler study was the only study with 
sufficient detail to adequately characterize the mass balance of inhaled iridium particles. 
Data from two additional studies were added in a stepwise manner in the current model: a 
second study of iridium particles (Kreyling et al., 2002, 2009), and a study of silver 
nanoparticles (Lankveld et al., 2010). Alteration in the agreement between the model 
predictions and the data was assessed as data sets were added.
Bayesian MCMC analyses were successfully completed for the Semmler data alone 
(Semmler et al., 2004; Semmler-Behnke et al., 2007) (“S analysis”); the Semmler data plus 
Kreyling data (Kreyling et al., 2002, 2009) (“SK analysis”), and the Semmler data, Kreyling 
data, and Lankveld data (Lankveld et al., 2010) (“SKL analysis”). A fourth study (Fabian et 
al., 2008; van Ravenzwaay et al., 2009) of titanium dioxide nanoparticles, which was also 
used in the preliminary model, was evaluated in the current model with the other three data 
sets. It took 32 attempts to find seed values that produced 5 complete chains when all four 
data sets were used. Several population parameter estimates generated by these chains failed 
to converge, so no further analysis of this output was conducted.
The statistical model parameters and results for the SK, S, and SKL analyses were 
summarized in Table 3, Tables S-1, and S-2, respectively. Convergence was seen for all 
parameters for the S and SKL analyses. A lack of convergence was observed for two 
parameters for the SK analyses—the sequestration rate in other perfused tissues (κ93) and 
the clearance of sequestered material from the heart (κ634). For the SK and SKL analyses, 
no substantial differences between the group-specific parameter values for the Semmler data 
vs. Kreyling data were identified (Table 3, Table S-1). For the SKL analyses, the Lankveld 
group parameter values were substantially different from those of the Semmler and Kreyling 
groups for fecal elimination and the plasma:liver partition coefficient (Table S-2).
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Monte Carlo simulations were conducted based on the population parameters from the S, 
SK, and SKL analyses. The predictions generated from the central tendency estimates of the 
population values were compared to the experimental data to generate a quantitative 
assessment of the agreement between the model and Semmler data (Table 4), Kreyling data 
(Table 5), and Lankveld data (Table 6). Graphical comparisons of the mean values of the 
experimental data and the 16th percentile, median, and 84th percentile values of the outputs 
of the SK and SKL analyses were also generated (Fig. 3—Semmler data, Fig. 4—Kreyling 
data, and Fig. S-2 in the Supplementary Materials—Lankveld data). Error bars for the 
experimental data are not shown; standard deviations for the Semmler et al. lung data were 
small (~17% of the mean, on average). Standard deviations on tissue concentrations 
appeared to be larger, at times exceeding 100% of the mean value, but could not be 
determined from the original paper due to lack of clarity in the original figure (overlapping 
error bars). Outputs from the S analyses were omitted from the figures for clarity and 
because of their similarity to the SK outputs. A data set not used in parameter estimation 
(Fabian et al., 2008) was also compared to model forecasts (Table S-3 and Fig. S-3).
Overall, the agreement to the Lankveld data was fair to poor, and the model tended to over 
predict the measured nanoparticle burdens, with the exception of the liver (Table 6, Fig. 
S-2). Because of this finding, the variability/uncertainty analysis was limited to the SK 
model to identify contributors to variability in predicted iridium disposition and inform the 
assessment of parameter identifiability from these data sets. Fixed parameters (Table 2) were 
not considered in this analysis. The analysis was limited to the population parameters 
determined through the Bayesian MCMC analysis, with sensitivity determined via rank 
correlation (i.e. rank of the input, among the 1000 trials vs. the rank of the forecast value 
derived from that trial) and percent contributions to variability determined from the squares 
of the correlation coefficients.
Optimized parameters that had the greatest impact on predicted brain concentration in 
iridium for the Semmler study are shown in Fig. 5. A larger estimated oral absorption rate 
tended to increase predicted brain concentrations, especially at the earliest sample time, 
while the fecal elimination rate had the opposite effect. The tissue-specific sequestration rate 
(κ83) and clearance rate for sequestered materials (κ834) had little impact at the earliest 
point, but were more important at later points, with impacts in opposite directions, while the 
impact of the plasma:brain partition coefficient is fairly consistent over time. The rate of 
sequestration in “other” tissues has some impact beyond the earliest time point due to its 
function as a relatively large sink for systemically-delivered nanoparticles. The time-
dependent contributions of the various parameters to the variability at each time point are 
shown in Fig. 6. Other systemic tissue concentrations had similar key determinants (data not 
shown). The amount in the lung and associated lymph nodes was sensitive to the rates of 
translocation from the lung to the blood (kb) and into the lymph nodes (kl), and was 
differentially sensitive over time to these parameters (Fig. 7). The cumulative amount 
excreted in feces was sensitive to some of the same parameters that drove the forecasted 
systemic levels (absorption, elimination, and sequestration in other tissues), and the same 
parameters to which lung burden was sensitive (Fig. 8).
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4. Discussion
The focus on the iridium data of Semmler and co-workers (Semmler et al., 2004; Semmler-
Behnke et al., 2007) for these analyses was due to the extended follow up (170 days post 
dosing) and potential for constraining mass balance (fecal excretion data; urinary excretion 
was likely minimal for this study due to particle size) and the previous use of these data in 
PBPK modeling of nanoparticles (MacCalman and Tran, 2009; MacCalman et al., 2009). 
The addition of the Kreyling et al. (2002, 2009) data was anticipated to better constrain the 
parameter estimates for systemically distributed iridium because of the availability of data 
for tissues not characterized by Semmler (e.g., one time point each for heart and blood and 
four time points for the other tissues compartment). It was determined that the addition of 
the Kreyling et al. (2002, 2009) data set, did not substantially alter the level of agreement, 
although optimal parameter values changed. Therefore changes in estimated parameter 
values between the “S” and “SK” analyses were not necessarily considered indicative of a 
poor model structure, but rather a reflection of better identification of parameter values due 
to consideration of additional data. Furthermore, the time course estimates for the median 
population simulation were still substantially in agreement with the experimental data (Table 
4) and the spread of the population simulations (84th vs. 16th percentile values) were 
narrower for the SK analysis than the S analysis (simulations not shown). The addition of 
the next data set (Lankveld et al., 2010) did not substantially alter the fit to the iridium data 
sets, but did not produce adequate agreement between experimental data and simulations for 
the silver nano-particles. In addition, inclusion of the third data set dramatically increased 
the spread of the posterior Monte Carlo population simulations of iridium toxicokinetics. 
This step-wise addition of data sets within the MCMC framework, rather than a single 
MCMC analysis of all of the data being considered, allowed us to discern the impact of each 
additional data set on model performance (i.e. fit) and precision of parameter estimates.
The sensitivity analyses for iridium kinetics demonstrated that the forecast values were 
clearly sensitive to most of the parameters being optimized. The time-sensitivity of the rank 
correlation co-efficients (Figs. 5 and 7) highlights the importance of time course data for 
evaluating model structures and parameterization. The determination that tissue burdens 
were sensitive to the values of many adjustable parameters was not surprising–had the tissue 
burdens been sensitive to a more limited set of parameters, the simpler model structures that 
were explored may have sufficed to fit the data.
The Lankveld et al. (2010) data were used to test the applicability of the iridium-derived 
parameters to the disposition of a similar material (with respect to size, lack of 
functionalization, etc.) in the same animal model, the young adult male Wistar rat. The fit of 
the median SKL simulation results to the Lankveld data was not acceptable (Table 6). The 
impact on simulations of the Semmler and Kreyling studies from the addition of the 
Lankveld et al. (2010) data to the MCMC analysis was not apparent from the predictions 
based on the central tendency population parameters values alone (Tables 4 and 5), but was 
evident in the wider population predictions (Fig. 3) and in an elevated estimate in the 
variance of the fecal excretion rate (Table S-2). This conclusion could not readily have been 
drawn from deterministic analyses alone, and helps demonstrate the value of the Bayesian 
approach. Had data on nanoparticle excretion in feces been available for the Lankveld et al. 
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(2010) study, the fecal excretion rate might have been more narrowly constrained. 
Dissolution of the silver nanoparticles at some rate may have contributed to poorer model fit 
and over-prediction compared to the calibration data (Fig. S-2) and an independent data set 
for titanium oxide nanoparticles (Fig. S-3).
The kinetics of nanoparticles in vivo are, in general, not currently well-understood (Li et al., 
2010) and the reasons for the inability of the iridium-derived model parameters to describe 
the toxicokinetics of silver (Lankveld et al., 2010) data are likewise unclear. One possibility 
is that there are key differences in the characteristics of the test articles that somehow 
translate to differences in optimal values for certain parameters; the data sets considered in 
this analysis were selected primarily based on similarity of particle size, and the lack of 
additional functional groups. Another possibility is that model structure does not adequately 
describe the key processes. The PBPK model structure tested here (a flow-limited 
modification of MacCalman and Tran, 2009; MacCalman et al., 2009), is based largely on 
model structures used previously for many volatile, soluble compounds, but with limited 
translocation from the lung interstitial tissue into the blood. A similar model structure was 
successfully applied to short term (up to 60 min) kinetics of 99mtechnitium-labeled carbon 
nanoparticles inhaled by humans (Péry et al., 2009). In contrast, Li et al. (2012) found the 
kinetics of poly(lactic-co-glycolic acid) nanoparticles prepared with varying amounts of 
monomethoxypoly (ethylene glycol) in mice were described better by membrane-limited 
models than flow-limited models. The model structure used herein for iridium particles did 
not include any saturable processes, and the doses of iridium nanoparticles (~3 μg in 
Semmler et al., 2004; Semmler-Behnke et al., 2007) were much less than the silver dose in 
Lankveld et al. (2010) (five injections of 23.8 μg), so the lack of consistency could be due to 
saturation of key processes at the higher doses in Lankveld et al. (2010). The model does, 
however, appear to capture the extent of the day-to-day increases in retention of 
nanoparticles in lung and peripheral tissues, consistent with the repeated-dosing data of 
Lankveld et al. (2010), the only repeated dosing study considered in this analysis. PBPK 
models for nanoparticles that integrate diffusion limited uptake and incorporate immune 
cells as a distinct, capacity-limited subcompartment could provide alternative structures to 
test against these same data sets (Bachler et al., 2013; Li et al., 2014). In addition, if the 
majority of systemically distributed nanoparticles are associated with macrophages, rather 
than “free”, their distribution over the time frame of interest here (several days) might better 
be described by inter-organ trafficking of the cells of the immune system (Zhu et al., 1996) 
rather than diffusion from blood alone. The simplistic description of sequestered particles 
being cleared directly to feces (rather than being trafficked through the lymphatic system or 
carried in the blood in a non-exchangeable form) contributes uncertainty to the derived 
parameters. However, since the parameters for clearance of sequestered particles do not 
have a significant impact on predictions of nanoparticle elimination in feces, the impact, if 
any, is likely limited to the fit to blood concentrations.
Further modeling work would benefit from well-conducted long-term kinetics studies in 
rodents, as discussed above. Even without such data, simulation studies may provide more 
information on the reliability of the current model parameter values as well as the potential 
to simplify the model structure for poorly-soluble nanoparticles. Moreover, further model 
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development to include particle dissolution pathways (e.g., as described in Bachler et al., 
2013) may improve the model predictions for soluble nano-particles. Although a goal of 
developing a PBPK model in rodents is to provide a biological basis for extrapolation of the 
model to humans, further data and model evaluations are needed before extrapolation is 
feasible. Ideally, future in vivo toxicokinetics studies of nanoparticles would incorporate 
better demonstration of mass balance, by collection of excreta and determination of nano-
particle content of all important tissues, including muscle, fat, bone marrow, and the 
skeleton at multiple time points. Multiple measurements of tissues are important so that both 
the delivery/distribution and clearance phases can be discerned, but this requires increased 
numbers of animals and amounts of test article. However, multiple measurements of blood, 
urine, and feces can be completed without requiring more animals or test article. While the 
sensitivity of tissue burdens of iridium to values of model parameters was fairly consistent 
after the initial distribution period (t = 6 h, vs. 7–170 days; Figs. 5–7), the cumulative 
excretion in the feces showed somewhat different patterns of sensitivity, depending on the 
parameter. For example, cumulative excretion showed a transient sensitivity to storage in 
“other” tissues, decreasing sensitivity to the oral absorption rate, and increasing sensitivity 
to the rate of transfer to the lymph nodes (Fig. 8). Thus, if analytical techniques permit 
quantitation of nanoparticles in excreta at longer times after administration, these data can 
provide useful constraints on model parameter values.
5. Conclusions
While the nanoparticle toxicokinetic database continues to expand (Yang et al., 2010), much 
remains unknown as to the fundamental processes which dictate the systemic uptake, 
distribution, and clearance from the body. PBPK modeling of nanoparticles is hampered by 
a lack of thorough mass balance studies with adequate time courses to supply sufficient data 
sets for comprehensive modeling; this lack may be overcome through better-designed 
studies, or techniques that allow information to be amalgamated across studies and study 
designs. In addition, it is important that the test articles be well-characterized so that 
properties beyond size and elemental composition (e.g., surface properties and other 
characteristics) be considered as potential key determinants of disposition. Bayesian MCMC 
techniques have the potential to be applied to test various model structures via the 
simultaneous consideration of multiple data sets over wide ranges of potential parameter 
values, facilitating an improved understanding of key determinants of toxicokinetics of 
different types of nanoparticles.
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Fig. 1. 
Structure of rat nanoparticle PBPK model.
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Fig. 2. 
Details of liver compartment structure and processes.
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Fig. 3. 
Disposition of iridium nanoparticles in rats exposed via a single intratratracheal intubation 
inhalation at 0.7 mg/m3 for 60–100 min. ■ Mean value of experimental data (Semmler et 
al., 2004; Semmler-Behnke et al., 2007; n = 8 up through day 59; n = 4 after day 59). Lines: 
PBPK model Monte Carlo simulations. Solid lines: median; dashed lines: 16th and 84th 
percentiles; black: SK analysis; gray: SKL analysis.
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Fig. 4. 
Disposition of iridium nanoparticles in rats exposed via a single intracheal tubation 
inhalation at 0.2 mg/m3 for 60–100 min. Symbols: mean experimental data of Kreyling et al. 
(2002, 2009); error bars not shown (fractional excretion and retention were reported 
graphically in the original data; the following coefficients of variation were estimated from 
the figures: 0.11 (lung), 0.14 (feces), 0.34 (brain), 0.44 (kidneys), 0.36 (liver), 0.44 (spleen), 
0.31 (heart), 1.03 (blood), and 0.18 (skeleton). Lines: PBPK model Monte Carlo 
simulations; solid lines—median; dashed lines—16th and 84th percentiles; black—SK 
analysis; gray—SKL analysis.
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Fig. 5. 
Rank correlation coefficient for optimized parameters and brain concentration at 0.25, 7, 21, 
or 170 days (from left to right, within each cluster) after inhalation exposure to iridium 
nanoparticles (Semmler et al., 2004; Semmler-Behnke et al., 2007). Only parameters with |
rank correlation| >0.2 for at least one sample time are shown.
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Fig. 6. 
Contributions of various parameters to variability in Monte Carlo-derived population 
simulations of nanoparticle concentrations in the brain in rats exposed to iridium by 
inhalation (per Semmler et al., 2004; Semmler-Behnke et al., 2007).
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Fig. 7. 
Rank correlation coefficient for optimized parameters and lung burden at 0.25, 7, 21, or 170 
days after inhalation exposure to iridium nanoparticles (Semmler et al., 2004; Semmler-
Behnke et al., 2007). Only parameters with |rank correlation| >0.2 for at least one sample 
time are shown.
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Fig. 8. 
Rank correlation coefficient for optimized parameters and cumulative excretion in feces at 
0.25, 7, 21, or 170 days after inhalation exposure to iridium nanoparticles (Semmler et al., 
2004; Semmler-Behnke et al., 2007). Only parameters with |rank correlation| >0.2 for at 
least one sample time are shown.
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Table 2
Fixed model parameters.
Value
Anatomical parameters (MacCalman and Tran, 2009; MacCalman et al., 2009)
Volume inhaled, L/min (VI) 0.18 (default)
Liver tissue volume, ml (Vtis3) 10.3
Liver capillary blood, fraction of liver tissue volume (Vcap3C) 0.06
GI tissue volume, ml (Vtis4) 6.0
GI capillary blood, fraction of GI tissue volume (Vcap4C) 0.0265
Kidney tissue volume, ml (Vtis5) 1.2
Kidney capillary blood, fraction of kidney tissue volume (Vcap5C) 0.13
Heart tissue volume, ml (Vtis6) 1.2
Heart capillary blood, fraction of heart tissue volume (Vcap6C) 0.1
Spleen tissue volume, ml (Vtis7) 0.6
Spleen capillary blood, fraction of spleen tissue volume (Vcap8C) 0.1
Brain tissue volume, ml (Vtis8) 1.2
Brain capillary blood, fraction of brain tissue volume (Vcap8C) 0.033
Venous plasma volume (Vven) 5.6
Arterial plasma volume (Vart) 11.3
Other tissues capillary blood, fraction of other tissues volume (Vcap9C) 0.1
Cardiac output, ml/day (QC) 1,201,200
Blood flow to liver (hepatic artery only), ml/day (Q3) 2523
Blood flow to GI tissue, ml/day (Q4) 16,704
Blood flow to kidneys, ml/day (Q5) 13,248
Blood flow to heart tissue, ml/day (Q6) 5616
Blood flow to the spleen, ml/day (Q7) 864
Blood flow to the brain, ml/day (Q8) 1872
Bile output, ml/day (Qbile) (RIVM, 2010) 20
Fecal elimination rate, day−1 (population mean) (Enck et al., 1989) 8.2
Alveolar region parameters (Tran et al., 2002)
Macrophage clearance rate, per day (kt) 0.015
Macrophage phagocytosis rate, per day (kr) 4.0
Macrophage death rate, per day (kd) 0.033
Interstitialization rate, per day (ki) 3.5
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Table 4
Discrepancies between model predictions and experimental data of Semmler et al. (2004) and Semmler-
Behnke et al. (2007).
Matrix (n)a Geometric mean discrepancy indexb
S Analysis SK analysis SKL analysis
Lung (20) 1.2 1.2 1.2
Feces (22) 1.0 1.1 1.1
Brain (4) 1.7 1.9 2.5
Kidney (5) 1.6 1.7 1.9
Liver (5) 2.0 4.4 3.5
Spleen (6) 2.5 3.2 3.1
All (63) 1.3 1.5 1.5
a
n = number of experimental data points for a specific matrix.
b
Discrepancy index = maximum of predicted value/measured value or predicted/measured value. Perfect agreement would have a discrepancy 
index of 1. Agreement considered acceptable if the discrepancy is, on average, <2 (IPCS, 2010).
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Table 5
Discrepancies between model predictions and experimental data of Kreyling et al. (2002, 2009).
Matrix (n)a Geometric mean discrepancy indexb
SK analysis SKL analysis
Lung (4) 1.1 1.1
Feces (6) 1.2 1.1
Brain (1) 1.0 3.8
Kidney (1) 2.1 9.9
Liver (4) 1.9 1.8
Spleen (1) 1.1 2.5
Heart (1) 1.0 6.1
Venous blood (1) 1.3 2.0
Other tissues (4) 5.1 1.5
All (23) 1.6 1.7
a
n = number of experimental data points for a specific matrix.
b
Discrepancy index = maximum of predicted value/measured value or predicted/measured value. Agreement considered acceptable if the 
discrepancy is, on average, <2 (IPCS, 2010).
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Table 6
Discrepancies between model predictions and experimental data of Lankveld et al. (2002 ,2009).
Matrix (n)a Geometric mean discrepancy indexb
SKL analysis
Lung (7) 10
Brain (7) 16
Kidney (7) 5.4
Liver (7) 2.2
Spleen (7) 9.0
Heart (7) 6.1
Venous blood (5) 1.5
All (47) 5.9
a
n = number of experimental data points for a specific matrix.
b
Discrepancy index = maximum of predicted value/measured value or predicted/measured value. Agreement considered acceptable if the 
discrepancy is, on average, <2 (IPCS, 2010).
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